Avandia User's Consumer Fraud Suit Dies In 3rd Circ.
GlaxoSmithKline LLC on Friday escaped the first of two proposed class actions on appeal in the Third Circuit in which users of the onetime blockbuster diabetes treatment Avandia are seeking refunds...To view the full article, register now.
Already a subscriber? Click here to view full article